Long-term ganciclovir prophylaxis for successful prevention of primary cytomegalovirus (CMV) disease in CMV-seronegative liver transplant recipients with CMV-seropositive donors.
Long-term ganciclovir prophylaxis for successful prevention of primary cytomegalovirus (CMV) disease in CMV-seronegative liver transplant recipients with CMV-seropositive donors.
复制标题
长期更昔洛韦预防可成功预防 CMV 血清阴性肝移植受者与 CMV 血清阳性供体的原发性巨细胞病毒 (CMV) 疾病。
作者：
P. Seu;D. Winston;C. Holt;F. Kaldas;R. Busuttil
BACKGROUND
We conducted a trial of long-term ganciclovir prophylaxis for prevention of primary cytomegalovirus (CMV) disease in CMV-seronegative liver transplant recipients with CMV-seropositive donors.
METHODS
Patients received intravenous ganciclovir at a dose of 6 mg/kg once a day from day 1 to day 30 after transplant, and then at a dose of 6 mg/kg once a day, Monday through Friday, until day 100. Forty-seven consecutive patients were evaluated. Due to the primary physician's decision or administrative error, 10 patients received less than 7 weeks of ganciclovir (mean duration, 3 weeks).
RESULTS
Four of the 10 (40%) patients who received less than 7 weeks of ganciclovir developed CMV disease (hepatitis). In contrast, none of the 37 patients given 100 days of prophylactic ganciclovir developed CMV disease while receiving ganciclovir. Two patients (5.4%) subsequently developed CMV disease (hepatitis) 21 and 88 days, respectively, after completing their ganciclovir prophylaxis. Reversible neutropenia in three patients (8.1%) was the only side effect associated with long-term ganciclovir. Complications from central intravenous catheters did not occur.
CONCLUSIONS
These results reaffirm the efficacy and safety of long-term ganciclovir prophylaxis for prevention of primary CMV disease in a large number of high-risk CMV-seronegative liver transplant recipients with CMV-seropositive donors.
抗病毒预防后患有 CMV 病毒血症的实体器官移植受者分离出的巨细胞病毒 (CMV) 更昔洛韦敏感性。
DOI：
10.1093/infdis/168.2.332
发表时间：
1993
期刊：
The Journal of infectious diseases
影响因子：
--
作者：
Boivin,G;Erice,A;Crane,DD;Dunn,DL;BalfourJr,HH
通讯作者：
BalfourJr,HH